<?xml version='1.0' encoding='utf-8'?>
<document id="21372830"><sentence text="Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib."><entity charOffset="69-78" id="DDI-PubMed.21372830.s1.e0" text="erlotinib" /></sentence><sentence text="To ascertain the effects of erlotinib on CYP3A, to investigate the amplitude and kinetics of erlotinib-mediated inhibition of seven major CYP isoforms in human liver microsomes (HLMs) for evaluating the magnitude of erlotinib in drug-drug interaction in vivo"><entity charOffset="28-37" id="DDI-PubMed.21372830.s2.e0" text="erlotinib" /><entity charOffset="41-46" id="DDI-PubMed.21372830.s2.e1" text="CYP3A" /><entity charOffset="93-102" id="DDI-PubMed.21372830.s2.e2" text="erlotinib" /><entity charOffset="216-225" id="DDI-PubMed.21372830.s2.e3" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e0" e2="DDI-PubMed.21372830.s2.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e0" e2="DDI-PubMed.21372830.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e0" e2="DDI-PubMed.21372830.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e0" e2="DDI-PubMed.21372830.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e1" e2="DDI-PubMed.21372830.s2.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e1" e2="DDI-PubMed.21372830.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e1" e2="DDI-PubMed.21372830.s2.e3" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e2" e2="DDI-PubMed.21372830.s2.e2" /><pair ddi="false" e1="DDI-PubMed.21372830.s2.e2" e2="DDI-PubMed.21372830.s2.e3" /></sentence><sentence text="" /><sentence text="The activities of 7 major CYP isoforms (CYP1A2, CYP2A6, CYP3A, CYP2C9, CYP2D6, CYP2C8, and CYP2E1) were assessed in HLMs using HPLC or UFLC analysis"><entity charOffset="56-64" id="DDI-PubMed.21372830.s4.e0" text="CYP3A" /></sentence><sentence text=" A two-step incubation method was used to examine the time-dependent inhibition of erlotinib on CYP3A"><entity charOffset="83-92" id="DDI-PubMed.21372830.s5.e0" text="erlotinib" /><entity charOffset="96-104" id="DDI-PubMed.21372830.s5.e1" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.21372830.s5.e0" e2="DDI-PubMed.21372830.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s5.e0" e2="DDI-PubMed.21372830.s5.e1" /></sentence><sentence text="" /><sentence text="The activity of CYP2C8 was inhibited with an IC(50) value of 6" /><sentence text="17±2" /><sentence text="0 μmol/L" /><sentence text=" Erlotinib stimulated the midazolam 1'-hydroxy reaction, but inhibited the formation of 6β-hydroxytestosterone and oxidized nifedipine"><entity charOffset="1-10" id="DDI-PubMed.21372830.s10.e0" text="Erlotinib" /><entity charOffset="88-110" id="DDI-PubMed.21372830.s10.e1" text="6β-hydroxytestosterone" /><entity charOffset="124-134" id="DDI-PubMed.21372830.s10.e2" text="nifedipine" /><pair ddi="false" e1="DDI-PubMed.21372830.s10.e0" e2="DDI-PubMed.21372830.s10.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s10.e0" e2="DDI-PubMed.21372830.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s10.e0" e2="DDI-PubMed.21372830.s10.e2" /><pair ddi="false" e1="DDI-PubMed.21372830.s10.e1" e2="DDI-PubMed.21372830.s10.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s10.e1" e2="DDI-PubMed.21372830.s10.e2" /></sentence><sentence text=" Inhibition of CYP3A by erlotinib was substrate-dependent: the IC(50) values for inhibiting testosterone 6β-hydroxylation and nifedipine metabolism were 31"><entity charOffset="24-33" id="DDI-PubMed.21372830.s11.e0" text="erlotinib" /><entity charOffset="92-104" id="DDI-PubMed.21372830.s11.e1" text="testosterone" /><entity charOffset="126-136" id="DDI-PubMed.21372830.s11.e2" text="nifedipine" /><entity charOffset="15-24" id="DDI-PubMed.21372830.s11.e3" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e3" e2="DDI-PubMed.21372830.s11.e3" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e3" e2="DDI-PubMed.21372830.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e3" e2="DDI-PubMed.21372830.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e3" e2="DDI-PubMed.21372830.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e0" e2="DDI-PubMed.21372830.s11.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e0" e2="DDI-PubMed.21372830.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e0" e2="DDI-PubMed.21372830.s11.e2" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e1" e2="DDI-PubMed.21372830.s11.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s11.e1" e2="DDI-PubMed.21372830.s11.e2" /></sentence><sentence text="3±8" /><sentence text="0 and 20" /><sentence text="5±5" /><sentence text="3 μmol/L, respectively" /><sentence text=" Erlotinib also exhibited the time-dependent inhibition on CYP3A, regardless of the probe substrate used: the value of K(I) and k(inact) were 6"><entity charOffset="1-10" id="DDI-PubMed.21372830.s16.e0" text="Erlotinib" /><entity charOffset="59-67" id="DDI-PubMed.21372830.s16.e1" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.21372830.s16.e0" e2="DDI-PubMed.21372830.s16.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s16.e0" e2="DDI-PubMed.21372830.s16.e1" /></sentence><sentence text="3 μmol/L and 0" /><sentence text="035 min(-1) for midazolam; 9" /><sentence text="0 μmol/L and 0" /><sentence text="045 min(-1) for testosterone; and 10"><entity charOffset="16-28" id="DDI-PubMed.21372830.s20.e0" text="testosterone" /></sentence><sentence text="1 μmol/L and 0" /><sentence text="058 min(-1) for nifedipine"><entity charOffset="16-26" id="DDI-PubMed.21372830.s22.e0" text="nifedipine" /></sentence><sentence text="" /><sentence text="The inhibition of CYP3A by erlotinib was substrate-dependent, while its time-dependent inhibition on CYP3A was substrate-independent"><entity charOffset="27-36" id="DDI-PubMed.21372830.s24.e0" text="erlotinib" /><entity charOffset="18-26" id="DDI-PubMed.21372830.s24.e1" text="CYP3A" /><entity charOffset="101-109" id="DDI-PubMed.21372830.s24.e2" text="CYP3A" /><pair ddi="false" e1="DDI-PubMed.21372830.s24.e1" e2="DDI-PubMed.21372830.s24.e1" /><pair ddi="false" e1="DDI-PubMed.21372830.s24.e1" e2="DDI-PubMed.21372830.s24.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s24.e1" e2="DDI-PubMed.21372830.s24.e2" /><pair ddi="false" e1="DDI-PubMed.21372830.s24.e0" e2="DDI-PubMed.21372830.s24.e0" /><pair ddi="false" e1="DDI-PubMed.21372830.s24.e0" e2="DDI-PubMed.21372830.s24.e2" /></sentence><sentence text=" The time-dependent inhibition of CYP3A may be a possible cause of drug-drug interaction, suggesting that attention should be paid to the evaluation of erlotinib's safety, especially in the context of combination therapy"><entity charOffset="34-38" id="DDI-PubMed.21372830.s25.e0" text="CYP3A" /></sentence><sentence text="" /></document>